Prescription weight-loss drugs
Examine the pros and cons of medications to treat obesity.By Mayo Clinic Staff
If you have serious health problems because of your weight — and lifestyle changes haven't resulted in significant weight loss — prescription weight-loss drugs may be an option. You should know, though, that prescription weight-loss drugs don't replace the need to make healthy changes in your eating habits and activity level.
Who is a candidate for weight-loss drugs?
Prescription weight-loss drugs are generally reserved for people who haven't been able to lose weight through diet and exercise, and who have health problems because of their weight. They're not for people who want to lose just a few pounds for cosmetic reasons.
Your doctor may consider weight-loss drugs for you if you haven't been able to lose weight through diet and exercise and you meet one of the following:
- Your body mass index (BMI) is greater than 30.
- Your BMI is greater than 27 and you have a serious medical problem related to obesity, such as diabetes or high blood pressure.
Before selecting a medication for you, your doctor will consider your health history, the possible side effects of the medications and any potential interaction of weight-loss drugs with other medications you're taking.
How well do weight-loss drugs work?
When combined with a low-calorie diet and regular exercise, weight-loss drugs produce an average weight loss of 5 to 10 percent of total body weight within a year, which is a typical weight-loss goal. Diet and exercise are responsible for part of this weight loss, and medications are responsible for part as well.
Losing 5 to 10 percent of your total weight may not seem like much, but even modest weight loss can improve your health by:
- Decreasing blood pressure
- Decreasing lipid levels
- Decreasing blood glucose levels
- Increasing insulin sensitivity
It's important to keep in mind, however, that these medications may not work for everyone. And when you stop taking these medications, you're likely to regain much or all of the weight you lost.
April 30, 2015
See more In-depth
- AskMayoExpert. Obesity. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
- Bray GA, et al. Obesity in adults: Drug therapy. http://www.uptodate.com/home. Accessed Jan. 27, 2014.
- Padwal RS, et al. Drug treatments for obesity: Orlistat, sibutramine and remonabant. The Lancet. 2007;369:71.
- Rucker D, et al. Long term pharmacotherapy for obesity and overweight: Updated meta-analysis. BMJ. 2007;335:1194.
- Meridia (sibutramine): Market withdrawal due to risk of serious cardiovascular events. U.S. Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm228830.htm. Accessed April 14, 2015.
- Completed safety review of Xenical/Alli (orlistat) and severe liver injury. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm. Accessed April 15, 2015.
- Xenical (prescribing information). South San Francisco, Calif.: Genentech USA, Inc.; 2010. http://www.gene.com/. Accessed April 15, 2015.
- Belviq (prescribing information). San Diego, Calif.: Arena Pharmaceuticals; 2012. http://invest.arenapharm.com. Accessed April 15, 2015.
- FDA approves Belviq to treat some overweight or obese adults. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm. Accessed April 14, 2015.
- FDA approves weight-management drug Qsymia. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm. Accessed April 15, 2015.
- Qsymia (prescribing information). Mountain View, Calif.: Vivus Inc.; 2012. http://www.vivus.com/products. Accessed April 15, 2015.
- Pollack A. FDA approves Qsymia, a weight-loss drug. New York Times. http://www.nytimes.com/2012/07/18/business/fda-approves-qsymia-a-weight-loss-drug.html. Accessed April 15, 2015.
- Allison DB, et al. Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP). Obesity. 2011;20:330.
- Medications target long-term weight control. U.S. Food and Drug Administration. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm312380.htm. Accessed April 15, 2015.
- Publication in Federal Register tomorrow moves Belviq (lorcaserin) closer to launch. Eisai, Inc. http://www.eisai.com/news/enews201326pdf.pdf. Accessed April 15, 2015.
- Didrex (prescribing information). New York., N.Y.: Pharmacia and Upjohn; 2010. http://www.pfizer.com/products/product-detail/didrex. Accessed April 15, 2015.
- Suprenza (prescribing information). Cranford, N.J.: Akrimas; 2012. http://www.suprenza.com/. Accessed April 15, 2015.
- Tenuate (prescribing information). Parsippany, N.J.: Actavis Pharma, Inc., 2012. http://www.actavis.com/. Accessed April 15, 2015.
- Bontril (prescribing information). Princeton, N.J.: Sandoz Pharmaceuticals, 2009. http://www.sandoz.com/. Accessed April 15, 2015.
- Contrave (prescribing information). Deerfield, Ill.: Takeda Pharmaceuticals America; 2014. http://www.takedapharm.com. Accessed April 15, 2015.
- FDA approves weight-management drug Contrave. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm. Accessed April 15, 2015.
- Apovian CM, et al. Guidelines on pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2015;100:342.
- FDA approves weight-management drug Saxenda. U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427913.htm. Accessed April 15, 2015.
- Saxenda (prescribing information). Plainsboro, N.J.: Novo Nordisk; 2015. http://novo-pi.nnittest.com/saxenda.pdf. Accessed April 15, 2015.
- Murphy JA, et al. Drugs in perspective: Liraglutide for the treatment of obesity. Formulary Watch. http://formularyjournal.modernmedicine.com/formulary-journal/content/tags/diabetes/drug-overview-liraglutide-treatment-obesity?page=full. Accessed April 15, 2015.